Evidence map›Paper›PMID 40430030›Full record

ArticleInternational journal of molecular sciences2025

Glycomics and Glycoproteomics Reveal Distinct Oligomannose Carriers Across Bladder Cancer Stages.

Marta Relvas-Santos, Dylan Ferreira, Andreia Brandão, Luis Pedro Afonso, Lúcio Lara Santos, André M N Silva, José Alexandre Ferreira

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marta Relvas-SantosExperimental Pathology and Therapeutics Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC Raquel Seruca), 4200-072 Porto, Portugal.ORCID 0000-0001-5764-5414
Dylan FerreiraExperimental Pathology and Therapeutics Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC Raquel Seruca), 4200-072 Porto, Portugal.ORCID 0000-0001-9224-0121
Andreia BrandãoCancer Genetics Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC Raquel Seruca), 4200-072 Porto, Portugal.ORCID 0000-0003-0938-1543
Luis Pedro AfonsoExperimental Pathology and Therapeutics Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC Raquel Seruca), 4200-072 Porto, Portugal.
Lúcio Lara SantosExperimental Pathology and Therapeutics Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC Raquel Seruca), 4200-072 Porto, Portugal.
André M N SilvaICBAS-School of Medicine and Biomedical Sciences, University of Porto, 4050-513 Porto, Portugal.ORCID 0000-0001-5554-7714
José Alexandre FerreiraExperimental Pathology and Therapeutics Group, Research Center of IPO Porto (CI-IPOP)/CI-IPOP@RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC Raquel Seruca), 4200-072 Porto, Portugal.ORCID 0000-0002-0097-6148

Funding

European Regional Development Fund NORTE-01-0145-FEDER-072678Portuguese Foundation for Science and Technology (FCT) PEst-OE/SAU/UI0776/201; 10.54499/LA/P/0008/2020; 10.54499/UIDB/50006/2020; https://doi.org/10.54499/SFRH/BD/146500/2019 and COVID/BD/153652/2024; https://doi.org/10.54499/2020.09384.BD; 2022.08311.CEECIND
6 · The paper itself

Abstract

Aberrant glycosylation is a hallmark of cancer, offering opportunities to enhance clinical decision-making and enable precise targeting of cancer cells. Nevertheless, alterations in the bladder urothelial carcinoma (BLCA)

Indexed as

GlycomicsGlycoproteinsMannoseOligosaccharidesProteomicsUrinary Bladder NeoplasmsFemaleGlycosylationHumansMaleNeoplasm StagingGlycoproteinsMannoseOligosaccharidesbladder cancerN-glycomicsN-glycoproteins

Identifiers

PMID40430030
PMCPMC12112682

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.